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Abstract Endometriosis, a chronic disease characterized
by endometrial tissue located outside the uterine cavity,
affects one fourth of young women and is associated with
chronic pelvic pain and infertility. However, an in-depth
understanding of the pathophysiology and effective treat-
ment strategies of endometriosis is still largely elusive.
Inadequate immune and neuroendocrine responses are
significantly involved in the pathophysiology of endome-
triosis, and key findings are summarized in the present
review. We discuss here the role of different immune
mechanisms particularly adhesion molecules, protein–
glycan interactions, and pro-angiogenic mediators in the
development and progression of the disease. Finally, we
introduce the concept of endometrial dissemination as
result of a neuroendocrine-immune disequilibrium in
response to high levels of perceived stress caused by
cardinal clinical symptoms of endometriosis.
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Introduction
Endometriosis, first described in 1860 by von Rokitansky,
is a chronic disease that is characterized by the occurrence
of endometrial glands and stroma outside the uterine cavity
[1]. Endometriosis affects up to 22% of women in their
reproductive age [2] and is associated with chronic pelvic
pain. Additionally, endometriosis is closely linked to
severely impaired fertility, as it can be diagnosed in 68%
of patients suffering from infertility [3]. To date, insights
into the pathophysiology of endometriosis, and thus the
development of effective treatment strategies, are surpris-
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e-mail: petra.arck@charite.deingly meager, which is attributed in part to the difficulties in
studying the disease in humans.
Various forms of endometriosis have been described,
such as endometriosis genitalis interna with endometrium
adjacent to the eutopic endometrium, e.g., within the
myometrium (adenomyosis) or the fallopian tubes.
Further, endometriosis genitalis externa is being referred
to if lesions can be located adjoining ovaries (endome-
triomas, endometriotic cysts), Douglas pouch, uterine
ligaments, vagina, vulva, or perineum. Additionally,
endometriosis extragenitalis mostly occurs within the
pelvic cavity, septum rectovaginale, intestine, and ureter
[4]. Deep infiltrating endometriosis, e.g., in the Douglas
pouch, the sacrouterine ligaments, or the septum retro-
vaginale, is a very painful form of endometriosis charac-
terized by fibrosis, smooth muscle proliferation, and
fibromuscular nodules; this clinical entity is also called
adenomysis externa [5]. According to Redwine [6], the
most common sites of pelvic endometriosis are the
Douglas pouch and the uterosacral ligaments.
A widely used classification of endometriosis has been
introduced by the American Society for Reproductive
Medicine (rASRM) and incorporates number, size, and
location of endometrial implants, endometriomas, and/or
adhesions as well as their morphology (red, white, and black)
yielding to a classification from stage 1 (minimal endometri-
osis) to stage 4 (severe endometriosis) [7]. The unambiguous
diagnosis of endometriosis is generally accepted by clini-
cians only after laparoscopic macroscopic evaluation and
subsequent histomorphometric analyses of biopsies. Non-
invasive diagnostic tools are not yet available.
Because the clinical symptoms of endometriosis range
from severe dysmenorrhea, dyspareunia, dysuria to
severe chronic pelvic pain, it is apparent that the disease
rigorously interferes with the patients’ quality of life and
affects social life, sexuality, and psychological well-
being. Accordingly, due to the link between endometri-
osis and infertility, quality of life is even further reduced
if women suffering from the clinical symptoms are
surplus childless. It has been proposed that infertility in
endometriosis patients might be due to altered folliculo-
genesis [8], reduced preovulatory steroidogenesis of
granulosa cells [9], and decreased capability of fimbrial
ovum capture in endometriosis [10]. Furthermore, sperm
phagocytosis by peritoneal macrophages [11]a n d
oviductal macrophages [12], anti-sperm antibodies [13],
and reduced sperm penetration and velocity [14]h a v e
been observed. In addition, an altered egg–sperm inter-
action [15] and toxicity against early embryonic devel-
opment [16], as well as defective implantation [17]h a v e
been proposed to be responsible for the infertility in
endometriosis patients.
Etiology
Different theories have been proposed to explain the
etiology of endometriosis: first and foremost, the trans-
plantation theory [18], which is based on observations
that retrograde menstruation of vital endometrium results
in the implantation of such tissue into the peritoneum. To
date, this theory is undeniably the most accepted concept.
However, it may be challenged by the fact that retrograde
menstruation is physiologically occurring in the majority
of women, but endometriosis only occurs in approxi-
mately one fourth of women in their reproductive years.
In this regard, endometriosis may be the result of a failing
immune surveillance in the peritoneal cavity in women
susceptible to endometriosis. Thus, immunologists should
become far more attentive to this disease, as insights on
its susceptibility, pathophysiology, and the identification
of therapeutic approaches are likely to arise from
immunologically based research. Another premise, the
so-called metaplasia theory, is based on the notion that
pluripotent coelomic cells differentiate into endometrial
cells [19]. This theory may provide explanation for deep
adenomyosis and relatively uncommon locations of
endometriosis such as the brain or the lung. On the other
hand, the denervation–reinnervation theory assumes that
damage and denervation during valsalva maneuvers are
followed by reinnervation [20] leading to a loss of uterine
polar contractility and promoting retrograde menstrua-
tion. Spread endometrial tissue then adheres to injured
tissue. Here, the extent of denervation and reinnervation
is interpreted as primary source for clinical symptoms and
their recurrence even after denervatory surgery. This
theory is supported by the fact that the majority of
patients with pelvic peritoneal defects and a history of
pain also suffer from endometriosis [21].
Additionally, various exposure factors are thought to
be associated to endometriosis, e.g., dioxin (2,3,7,8-
tetrachlorodibenzo-p-dioxin) [22]. Here, the idea is that
dioxin promotes the development of endometriosis by
interfering with immune-mediated mechanisms, more
specifically by stimulating the production of pro-inflam-
matory cytokines. A genetic etiology has also been
proposed due to the high prevalence in relatives of
affected women [23]. Although a wealth of genetic
factors have been anticipated to be linked to an increased
susceptibility to endometriosis [24], generally accepted
marker gene(s) for endometriosis could not yet be
identified. Emerging evidence points towards differential
gene expression in eutopic and ectopic endometrium in
humans [25, 26], and future research will be needed to
provide a more in-depth understanding of the biological
significance of this disease.
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Because endometrial lesions are frequently present in the
peritoneal cavity, they are in direct contact with peritoneal
fluid, which bathes the pelvic cavity, uterus, fallopian tubes,
and ovaries. However, in endometriosis, ectopic endome-
trial cells escape pathways involved in immune-mediated
surveillance. In search for a better understanding of the
pathogenesis of endometriosis, here, we analyzed different
immune-mediated mechanisms and mediators that might be
involved in disease development and resolution.
Role of innate immune responses in endometriosis
Macrophages
Macrophages are the main population of peritoneal leuko-
cytes and—according to the published evidence so far—
comprise up to 90% of peritoneal fluid cells [27]. In women
suffering from endometriosis as well as in baboons with
spontaneously occurring mild endometriosis, the concen-
tration of peritoneal macrophages is increased as compared
to healthy or infertile controls or animals with normal
pelvis, respectively [27, 28]( F i g .1). However, their
percentage of total mononuclear cells seems to be decreased
in favor of lymphocytes [29]. Further, an increased percent-
age of peritoneal macrophages is positive for the cell
activation marker acid phosphatase in mild endometriosis
[30]. Increased cell counts may be attributable to elevated
levels of macrophage colony-stimulating factor (M-CSF)
[31] and monocyte chemotactic protein (MCP)-1 [32]
(Fig. 1). Here, M-CSF and MCP-1 have been proposed to
derive from endometrial/endometriotic cells or peritoneal
macrophages, respectively.
In vitro studies revealed that peritoneal macrophages
derived from patients with endometriosis produce
increased levels of the cytokines interleukin (IL)-6
[33], IL-1β, and tumor necrosis factor (TNF)-α [34],
compared to peritoneal macrophages of women with other
benign gynecological disorders (Fig. 1). Because IL-6,
IL-1β,a n dT N F - α promote the adhesion of endometrial
cells to peritoneum, increased secretion of these cytokines
by peritoneal macrophages in patients with endometriosis
might contribute to the development and progression of
the disease [35]( F i g .1). It is further noteworthy that
IL-6, IL-1, and TNF-α correlate with infertility and
embryotoxicity when secreted at high levels [36, 37].
Further, TNF-α induces proliferation of ectopic stromal
cells, which would subsequently result in the growth of
endometriotic lesions [38]( F i g .1). Moreover, TNF-α
target genes have been proposed to be overexpressed in
experimental endometriosis in rats [39].
Elevated prostaglandins (PG), particularly PGE2 in the
peritoneal fluid of endometriosis patients [40] (Fig. 1), may
result from macrophage activation and have been proposed
to subsequently aggravate endometriosis-associated pain by
altering uterine and tubal contractility and cause infertility
due to a delayed ovum transport [41]. On the other hand,
emerging evidence addresses the decrease in human
leukocyte antigen (HLA)-ABC and HLA-DR on peritoneal
macrophages in endometriosis patients (Fig. 1), suggesting
defective antigen presentation [42]. In advanced stages,
macrophage-mediated cytotoxicity against endometrial cells
is reduced as compared to early stages [43] (Fig. 1).
Interestingly, cytotoxic activity could be restored by
application of the non-steroidal, PG-inhibiting drug indo-
methacin, which points towards a dampening effect of PG
on macrophage cytotoxicity in endometriosis [43] (Fig. 1).
In early stages, however, the cytotoxicity of peritoneal
macrophages is increased compared to fertile controls.
Thus, hypothetically, activated macrophages in the perito-
neal fluid may control the number and size of peritoneal
endometriotic lesions. On the other hand, a wealth of
mediators derived from peritoneal macrophages such as the
abovementioned cytokines may promote adherence and
proliferation of endometrial cells and angiogenesis, thus
facilitating the dissemination of endometriotic lesions. In
conclusion, additional work aiming to dissect the role of
peritoneal macrophages in endometriosis is needed.
Mast cells
Mastcells playa pivotalrolewithininnateimmuneresponses.
In addition, these cells play a critical role in sustaining Th2-
mediated responses by secreting high levels of IL-4. Because
mastcellsarepredominantlyresidentcellsoflooseconnective
tissue, mast cells’ presence and function have been investi-
gated in endometriotic tissue [44]. Here, Kempuraj et al.
observed increased numbers of highly activated mast cells in
the stroma of peritoneal endometriotic lesions as compared
to eutopic endometrium (Fig. 1). Mast cell migration and
proliferation may be related to increased levels of stem cell
factor (SCF) in the peritoneal fluid of women with early
stage endometriosis and the expression of its cognate
receptor on ectopic endometrium [45], whereby SCF may
derive from fibroblasts, endothelial, and granulosa cells [46].
Activated mast cells release enzymes, such as tryptase,
which stimulate protease-activated receptor (PAR)-2. Strik-
ingly, PAR-2 agonist induces proliferation of purified
endometriotic stromal cells and the release of IL-6 and IL-
8i nv i t r o[ 47]( F i g .1). Especially in deep infiltrating
endometriosis, mast cells were found near nerve fibers. This
led to the suggestion that mast cells might play a pivotal role
in endometriosis-related pain [48].
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Natural killer (NK) cells play a pivotal role at the crossroads
of innate and adaptive immunity not only through their
ability tolyse infectedor tumor cells butalso bythe secretion
of cytokines that contribute to direct selective adaptive
responses. Published data indicate that NK cells derived
from peripheral blood, characterized by markers such as
CD16 and CD57, are involved in the cytotoxicity against
endometrial cells in vitro [49]. The cytotoxic activity of
peritoneal NK cells derived from endometriosis patients
against NK-cell-sensitive K562 target cells was shown to
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Fig. 1 Neuroendocrine–immune disequilibrium in endometriosis. AAb
autoantibodies, Ach achetylcholine, CGRP calcitonin-gene-related pep-
tide, CRH corticotropin-releasing hormone, E estrogens, E2 estradiol,
Hb hemoglobin, HO heme oxygenases, IL interleukin, HLA human
leukocyte antigen, IFN-γ interferon-γ, KIR killer cell inhibitory
receptor, M-CSF macrophage colony stimulating factor, MCP-1
monocyte chemotactic protein-1, MHC-I major histocompatibility
complex class-I, MMP matrix metalloproteinase, NGF nerve growth
factor, NK natural killer, P progesterone, PAR-2 protease-activated
receptor-2, PGE(2) prostaglandin E(2), pHp peritoneal haptoglobin,
RANTES regulated upon activation normal T cell expressed and
secreted, sCD23 soluble CD23, SCF stem cell factor, sICAM-1 soluble
intercellular adhesion molecule-1, SP substance P, TGF-β transforming
growth factor-β, TH tyrosine hydroxylase, TNF-α tumor necrosis
factor-α, VEGF vascular endothelial growth factor. In endometriosis,
elevated levels of M-CSF, MCP-1, RANTES, and SCF in peritoneal
fluid might lead to increased numbers of macrophages, Tcells, and mast
cells. Although markers of antigen presentation on macrophages such as
HLA-ABC and HLA-DR are decreased in endometriosis, macrophage-
derived IL-6, IL-1β, TNF-α, TGF-β, VEGF, and IL-8 are increased in
peritoneal fluid, together with MMP-1 and MMP-2 stimulating
angiogenesis. IL-6, IL-1β, and TNF-α support adhesion of endometrial
cells to the peritoneum, and TNF-α stimulates the proliferation of
ectopic tissue, resulting in high levels of Hb. T cell-derived IL-2 and
IFN-γ decrease HO, leading to oxidative stress, and would, in sufficient
levels, increase NK cell activity. IFN-γ has been inconsistently
described as increased or decreased. Increased T cell-derived IL-4 and
IL-10 inhibit cellular immunity and stimulate B cells to AAb
production. sCD23 is increased in peritoneal fluid in endometriosis
and might derive from activated B cells. Lymphocytes are increased in
peritoneal fluid and abundantly present in ectopic tissue. Decreased NK
cell cytotoxicity might be due to high anti-inflammatory T cytokines,
increased KIR, high macrophage-derived PGE(2) and TGF-β,h i g h
MHC-I expression on ectopic cells, and high sICAM-1 levels in
peritoneal fluid. Nerve fibers found within lesions are positive for
CGRP, SP, TH, and Ach, and NGF and CRH were demonstrated. CRH
and accumulated E can activate mast cells to release tryptase, activating
PAR-2, which leads to increased secretion of VEGF, IL-8, and IL-6 and
proliferation of ectopic tissue. pHp, expressed by ectopic tissue,
decreases adherence and, in stage 3 and 4, cytotoxicity of peritoneal
macrophages. E2 further increases RANTES, IL-8, and VEGF, whereas
P inhibits IL-1β secretion from peritoneal macrophages and increases
NK cell numbers
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regards to the percentages of NK cells within the peritoneal
fluid among different patients. Nevertheless, the alterations
in cytotoxicity seem to depend on a functional defect of NK
cell activity in endometriosis rather than differences in the
total cell number [50]. One explanation for such a decrease
in NK cell activity might rely on the increased levels of
transforming growth factor (TGF)-β [52] and PGE2 [40]i n
peritoneal fluid of women with endometriosis, which both
inhibit NK cell activity and are derived from macrophages
(Fig. 1). A second explanation for the reduced function of
these cells in endometriosis involves a group of receptors
referred to as killer cell inhibitory receptors (KIR). These
receptors recognize major histocompatibility complex class
I (MHC-I) antigens, which inhibit cytotoxicity against
MHC-I-expressing target cells. Interestingly, the expression
of KIRs on peritoneal NK cells of women with endome-
triosis is increased [53]( F i g .1). Insights on MHC
expression of endometriotic lesions are surprisingly mea-
ger; however, in a recent study using cDNA microarray
technique, an up-regulation of genes encoding MHC
antigens could be detected on ovarian endometrial cysts
[54], which would support the notion of an escape of NK-
cell-mediated cytotoxicity induced by the endometriotic
lesion itself. Strikingly, in severe endometriosis, endometri-
otic cells are also more resistant to lysis by heterologous
NK cells derived from peripheral blood [49], which further
supports the immune escape theory.
Role of adaptive immune responses in endometriosis
The absolute number as well as the relative percentage of
lymphocytes in peritoneal fluid of endometriosis patients
have been shown to be significantly augmented [29].
T cells
Endometriotic lesions may be considered as an ‘autologous
transplant’; nonetheless, one might expect T cells in the
peritoneal fluid to be a candidate population in the rejection
of endometric tissue. Indeed, T cells expressing markers
such as CD3, CD4, and CD8 have been described to be
elevated in endometriotic tissue [55, 56] (Fig. 1). RANTES
(short for ‘regulated upon activation normal T cell
expressed and secreted’), chemoattractant, e.g., to T cells,
is expressed in ectopic endometrium [57] and elevated in
the peritoneal fluid in endometriosis [58] (Fig. 1), which
might explain the high number of T cells within the lesion.
However, an in-depth analysis of the frequency of T cells
and, in particular, their functional differentiation into
cytotoxic (CD8
+) or helper (Th1, Th2, or Th17 cells) cell
subsets in peritoneal fluids of endometriosis patients still
remains elusive.
Surprisingly, no published evidence is currently avail-
able whether or not regulatory T cells (Treg) [59] are
involved in the undesired ‘immunological tolerance’ of
endometriotic lesions. Autoreactive T cells are capable of
encountering self-peptide/MHC complexes. Hence, the
basic importance of Tregs in the maintenance of immune
cell homeostasis is to suppress such autoreactive T cells.
One might speculate that, in the context of endometriosis, it
may be desirable to have autoreactive T cell-like popula-
tions in the peritoneal fluid, which may be capable of
targeting the autologous endometriotic transplant. Hence,
the presence of peritoneal Treg—which could suppress
such autoagressive cells—would be undesired. However,
no published data indicate the existence of autoreactive T
cell-like populations in the peritoneal cavity of women
without endometriosis, which could provide an explanation
for the successful deletion of endometrial tissue entering the
peritoneal cavity by retrograde menstruation in these
women.
Natural killer T (NKT) cells are also cells that bridge
innate and adaptive immune mechanisms. They produce a
wide range of cytokines, mainly IL-4, driving the develop-
ment of Th2-mediated responses and recognize glycolipids
associated to CD1d molecules. Therefore, it appears rather
puzzling that no published evidence is currently available
indicating the presence or function of such cells in peritoneal
fluid in the context of endometriosis.
Various authors have addressed the issue of Th1/Th2
cytokine balance in the peritoneal fluid of patients with endo-
metriosis.Severalofthesecytokinesmaybeproducedbycells
of the adaptive immune response, and especially the ratio of
pro-inflammatory Th1-like and anti-inflammatory Th2-like
cytokines has been in the center of scientific attention. In
endometriosis, the production of pro-inflammatory interferon
(IFN)-γ and IL-2 as well as the anti-inflammatory cytokines
IL-4 and IL-10 was found to be increased in peritoneal fluids,
although controversial data have been published especially
with regard to IFN-γ [29, 60, 61]( F i g .1). Th1 cytokines
such as IFN-γ and IL-2 are well known to lead to the
activation of T cell-mediated and delayed-type hypersensi-
tivity (Fig. 1). On the other hand, Th2 cytokines such as IL-4
and IL-5 stimulate antibody-mediated immunity via B cell
differentiation to plasma cells and inhibit Th1-mediated
responses (Fig. 1). Whether endometriosis is a typical Th1-
or Th2-mediated disease is not clear. In addition, future
studies are warranted on the role of the recently identified
pro-inflammatory Th17 cells, which secrete high levels of
IL-17A, IL-17F, IL-6, and TNF-α and sustain tissue damage.
A pro-inflammatory status has been proposed to result in
the down-regulation of heme oxygenases (HOs) [62]
(Fig. 1). HOs are required to degrade heme into biliverdin
and carbon monoxide (CO) to avoid toxic heme effects
such as oxidative stress; hence, HOs have been proposed to
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endometrial tissue leads to high levels of hemoglobin
(Fig. 1) as well as heme, which requires adequate HO
activity to sustain tissue protection. Hemoglobin [63]a s
well as markers of oxidative stress such as lipid peroxides
[64] are elevated in patients with endometriosis (Fig. 1).
Thus, it has been suggested that the HO system might be
insufficient to detoxify heme in women with endometriosis.
Such insufficiency of the HO system may result from the
continuous pro-inflammatory environment in the peritoneal
cavity of patients with endometriosis. As a consequence of
the insufficient HO system, high levels of oxidative stress
may further enhance adhesion of more refluxed endometrial
cells onto the peritoneum during menstruation and perpet-
uate the progression of endometriosis (Fig. 1).
Interestingly, recombinant human TNF-binding protein-1
reduces experimental endometriosis in rats [65], supporting
the notion of an adverse effect of this pro-inflammatory
cytokine. In contrast, intraperitoneal injection of the Th1-
like cytokine IL-12 also reduces endometriotic lesions in
vivo [66], probably by enhancing cytotoxic activity. It is,
thus, not finally resolved whether pro- or anti-inflammatory
responses or both of them should be suspected to contribute
to the development of endometriosis.
B cells
B cells are involved in antibody-mediated adaptive immune
responses. While B2 cells can give rise to classical plasma
cells producing many distinct immunoglobulin (Ig) isotypes
(IgG, IgA), other B cell types including B1 cells, which are
present in the peritoneal cavity, and BZM cells, which are
located in the marginal zone of the spleen, produce only
high levels of IgM to T-independent antigens. An increase
in activated CD20
+ B cells could be demonstrated in
ectopic endometrium [67] (Fig. 1). Soluble CD23, which
may be derived from mature B cells and also from activated
macrophages, eosinophils, follicular dendritic cells, and
platelets, is increased in serum and peritoneal fluid of
endometriosis patients, which may be suggestive of an
exacerbated B cell activation in endometriosis [68] (Fig. 1).
In addition, an increase in autoantibodies (AAb) such as
anti-phospholipid and anti-histone IgG could be detected in
the peritoneal fluid of endometriosis patients [69] (Fig. 1).
Serum and cervical secretions of women with endometriosis
contain organ-specific anti-endometrial and anti-ovarian
specific IgG and IgA, suggesting the activation and plasma
cell differentiation of B2 cells [70].
Some of the antigens from endometriotic tissue, which
are recognized by serum AAb, have been identified; these
include mainly glycoproteins including the human chori-
onic gonadotropin (hCG) receptor [71], carbonic anhydrase
isoforms I and II [72, 73], transferrin, and α2-Heremans
Schmidt glycoprotein (α2-HSG) [74]. Interestingly, Lang
and Yeaman [73] demonstrated that removal of carbohy-
drate moieties from endometrial antigens prevented antibody
binding via Thomsen–Friedenreich disaccharide-dependent
pathways. Thomsen–Friedenreich antigens, which are
expressed on epithelial cells of the uterus, bind to a variety
of glycan-binding proteins including galectin (Gal)-1 and
Gal-3, which are also expressed in endometrial tissue. Gal-1
and Gal-3 are evolutionarily conserved glycan-binding
proteins that have been shown to contribute to cell–cell and
cell–matrix interactions, cell migration, and angiogenesis
[75]. In addition, galectins have been shown to modulate
T cell apoptosis and immune privilege in vivo [76], thus
contributing to autoimmunity by dampening antigen-specific
immune responses. Because levels of AAb against Thomsen–
Friedenreich antigen are significantly up-regulated in endo-
metriosis tissue, it is possible that these AAb might block or
mimic some of the biological functions of galectins. How-
ever, to date, no data are available indicating the regulated
expression of Gal-1 and Gal-3 in endometriotic tissue.
In conclusion, AAb might be directly involved in the
pathogenesis of endometriosis supporting an autoimmune
etiology. However, AAb against Thomsen–Friedenreich
antigen could also be an autoimmune epiphenomenon due
to aberrantly glycosylated endometrial antigens. If the latter
assumption is correct, it would be of great interest to
investigate cells of the adaptive immune response with
regard to the recognition of such altered self-antigens.
Adhesion molecules and protein–glycan interactions
in endometriosis
Due to the prevailing inflammation in endometriosis, adhe-
sion molecules have been suggested to be involved, e.g., by
mediating the migration of leukocytes into the peritoneal
cavity. In this context, published data point towards altered
cell adhesion mechanisms, which might interfere with
leukocyte function. The following scenarios might—at least
in part—provide an explanation for the failing immune
surveillance in endometriosis. First, leukocyte function
antigen (LFA)-1
+ effector cells interact with intercellular
adhesion molecule (ICAM)-1 expressed by target cells,
whereby soluble ICAM-1 (sICAM-1) may interfere with
such interactions. In endometriosis, the severe decrease in
NK cell-mediated lysis of endometrial cells could be
manifested when endometrial supernatants contained high
levels of sICAM-1 (Fig. 1), whereby it remains to be fully
elucidated whether peritoneal NK cells express LFA-1 [66].
Strikingly, the expression of sICAM-1 by ectopic endome-
trium is increased as compared to eutopic endometrium [77],
and the levels of sICAM-1 are elevated in peritoneal fluid of
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lesions may ‘neutralize’ peritoneal LFA-1
+ effector leuko-
cytes via sICAM-1, which results in impaired immune
surveillance of such effector cells.
A second putative scenario involves the glycoprotein
peritoneal haptoglobin (pHp) or endometriosis protein-I
(Endo-I). This glycoprotein is highly expressed in perito-
neal endometriotic lesions [79] (Fig. 1) and interacts with
various lectins or glycan-binding proteins [80]. Increased
interaction of pHp with different lectins might be due to
variations in the ratios of α(2–3) to α(2–6) sialic acid and
fucose [80]. These alterations could be connected to
increased expression of glycans mainly involved in carbo-
hydrate–selectin interactions and cell–cell adhesion. Some
studies report increased expression of E- and P-selectins in
endometriosis [39, 81]. Because several reports are contro-
versial [82], one might hypothesize that the function of
selectins, determined by the binding to their epitopes, is
more important than their quantitative levels. Sharpe-Timms
et al. [83] showed that peritoneal macrophages from women
with endometriosis bind more pHp in vivo than those from
women without the disease, although the concentration of
pHp is similar in both groups. The authors speculate that
this effect may be due to altered forms of haptoglobin.
Glycoproteins with increased numbers of glycans contain-
ing Sialyl-Lewis X structures are able to block adhesions of
immune cells [84, 85], which may provide an explanation
for the decreased ability of peritoneal macrophages to
mediate cytolysis of misplaced endometrial tissues, as
detectable in the peritoneal cavity (Fig. 1), which is further
associated with an increased resistance of these cells to
apoptosis in women with endometriosis [83].
Glycosylation and morphological changes were further
investigated in a baboon model of endometriosis, and an
increased lectin binding to fucosylated N-acetylglucos-
amine residues could be detected in early stages of the
disease, whereas such binding—accompanied by a late
secretory phenotype of endometrial glands—was
decreased in later stages of the disease [86]. A clear
evidence of an asynchrony between the estimated day of
the menstrual cycle and the observed histological/ultra-
structural appearance of the glands could be identified.
Fucosylated N-acetylglucosamine residues are essential for
the adhesion of the hatched blastocyst to the endometrium
[87]. Glycosylation is important in the regulation of
embryo attachment, and differential glycosylation can be
regulated in the endometrium by the action of several
hormones mainly during the secretory phase [88]. There-
fore, one might speculate that abnormal glycosylation in
endometriosis may be one of the factors leading to reduced
fertility and other clinical and pathological manifestations
of the disease.
Angiogenesis in endometriosis
The establishment of a new blood supply is essential for the
survival of endometrium attached to the peritoneum and the
maintenance of endometriosis. Increased microvessel den-
sity in endometriotic tissue with high proliferative activity
has been demonstrated compared to lesions with low
proliferative activity [89], which could be inhibited by
blocking vascular endothelial growth factor (VEGF) [90].
High levels of VEGF and more specifically VEGF-A are
present in peritoneal fluid of endometriosis patients [89]
(Fig. 1). Other macrophage- or mast cell-derived factors,
which either directly or indirectly induce angiogenesis and
are up-regulated in endometriosis, include IL-1, IL-6, TNF-
α, and TGF-β [91–93] (Fig. 1). In addition, IL-8 is
increased in peritoneal fluid in endometriosis [94] and
contributes to angiogenesis [95] (Fig. 1). Finally, matrix
metalloproteinases (MMP) are involved in tissue remodel-
ing and angiogenesis. The expression of MMP-1 by
endometriotic cells is increased as compared to eutopic
endometrium of patients and controls [96], and levels of
MMP-2 were found to be elevated in peritoneal fluid of
endometriosis patients [97] (Fig. 1). In contrast, another
study reported MMP-1 and MMP-2 to be highly expressed
in eutopic but not ectopic endometrium of women with
endometriosis and a decrease in the MMP-2 inhibitor
(TIMP-2) [98], suggesting a role of MMP in the very early
development of the disease.
It may be concluded that immune cells in the peritoneal
fluid and probably within the lesions do not only fail to
reject endometriotic lesions but also support their growth
by promoting vascularization and thus nourishing of the
tissue with their secreted factors such as cytokines.
The role of steroid hormones in endometriosis
Circumstantial and laboratory evidences are indicative of
critical roles of steroid hormones in the establishment and
maintenance of endometriosis. A lower incidence of the
disease is noted in women with decreased endogenous
estrogen production due to extensive exercise or smoking
[99]. Although the development of endometriosis has
historically been viewed as an estrogen-dependent disease,
recent studies suggest that a failure of progesterone to
appropriately regulate the expression of genes during
endometrial differentiation might be a critical component of
the disease process. It is well accepted that progesterone
inhibits estradiol (E2)-dependent proliferation in the uterine
epithelium. In humans and other vertebrates, the biological
activities of progesterone are mediated by interaction with
Semin Immunopathol (2007) 29:193–210 199specific progesterone receptors (PRs) that are members of
nuclear receptor superfamily of transcription factors. In
contrast to healthy endometrium, hormone receptors remain
at constant levels during the menstrual cycle in endometri-
osis [100], which points at a disruption of the normal cyclic
responsiveness to hormonal changes with regular apoptosis
of the epithelial stratum functionalis in endometriotic lesions.
The following molecular observations support a role of
progesterone in endometriosis. First, a PR gene polymorphism
was reported to be associated with endometriosis [101]
(Fig. 2b). Second, only low levels of PR isoform A (PR-A)
and no PR-B are detectable in extraovarian endometriosis
[102]( F i g .2b). Third, progesterone-dependent regulation of
target genes was found to be perturbed in endometriosis. In
the normal secretory endometrium, progesterone indirectly
induces the 17β-hydroxysteroid dehydrogenase type 2 (17β-
HSD-2), which converts estradiol (E2) to estrone (E1) [103]
(Fig. 2a). In endometriotic tissue, 17β-HSD-2 is undetectable
[104]( F i g2b). As a consequence, E2 accumulates and
probably induces proliferation of endometrial tissue. More-
over, the enzyme aromatase is exclusively found in endo-
metriotic stroma [105] and provides E1, which is further
converted to E2 by 17β-HSD type 1 (17β-HSD-1),
contributing to the accumulation of E2 (Fig. 2b). The
importance of aromatase for the endometriotic growth has
been demonstrated by its genetic or enzymatic disruption
[106].
Besides, E2 might also be involved in endometriosis-
related inflammation, as it stimulates several mediators of
inflammation such as IL-8 and RANTES [57, 107] (Fig. 1).
Levels of MMP-2 in peritoneal fluid positively correlate
with E2, but inversely with progesterone [97], and estro-
gens can also co-stimulate peritoneal mast cell activation in
rats [108] (Fig. 1). Further, both E2 and progesterone
increase the release of VEGF from peritoneal macrophages
[109] and may hereby promote angiogenesis in endometri-
otic lesions. Given the high levels of E2 within the lesion,
E2 might be more relevant in this context.
In contrast to estrogens, progesterone or synthetically
produced progestogens called progestins exert potent im-
eutopic endometrium ectopic endometrium
PR-A             PR-B PR-A              PR-B
17β-HSD-2
E2              E1
17β-HSD-2
aromatase
P “P resistance” P
E1   E2
17β-HSD-1
aromatase
cyclic proliferation
and apoptosis
proliferation
PR gene polymorphism
ab
E2        (E1)
Fig. 2 Progesterone resistance and estradiol accumulation in endo-
metriosis. E1 estrone, E2 estradiol, P progesterone, PR progesterone
receptor, 17β-HSD-1 17β-hydroxysteriod dehydrogenase type 1, 17β-
HSD-2 17β-hydroxysteriod dehydrogenase type 2. a In normal
endometrium, P actions are mediated by PR; its isoforms PR-A and
PR-B are both expressed on the tissue. P indirectly induces 17β-HSD-
2, which converts E2 to E1; aromatase is not expressed. Tissue
proliferation is followed by cyclic apoptosis. b In endometriotic tissue,
only low expression of PR-A and the lack of PR-B have been
observed, which leads to a partial resistance to P actions. Additionally,
a PR gene polymorphism has been described to be more frequent in
patients with endometriosis, which may be additionally involved in
the partial resistance to P actions. Low levels of 17β-HSD-2 along
with the enzymatic activity of aromatase—which is exclusively found
in endometriotic stroma—lead to an accumulation of E2. Hence,
physiological cyclic regulation of proliferation and apoptosis is
disrupted in endometriosis
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ing inflammation have been demonstrated for the progestin
dydrogesterone [110–112]. Using other progestins available
to date, a reduction in transplant growth, a degeneration of
transplants, an increase in NK cells in peritoneal fluid, and
a decrease in IL-1β secretion from peritoneal macrophages
could be demonstrated [113–115] (Fig. 1). It would be
interesting to investigate the cross talk between hormones
and regulatory T cells in this process.
One might conclude from these observations that E2
promotes endometriosis and progesterone/progestins damp-
en it, which is the rationale why progestins are widely used
to treat endometriosis. In general, they act as agonists on
the PR and have a functional anti-proliferative effect on
endometrial tissue and endometriotic lesions. In addition,
progestin treatment is generally better tolerated than other
endometriosis therapies, which are associated with rather
severe side effects [116]. Importantly, progestins are known
to be effective in the control of pain symptoms in general or
related to endometriosis [112, 116, 117]. However, not all
patients respond to this regimen [118]. This clinical
observation may be explicable by the partial resistance of
endometriosis tissue to progesterone action due to the
down-regulation of its receptors, as outlined earlier.
Neurological aspects in endometriosis
The female reproductive organs are innervated by sympa-
thetic, parasympathetic, and sensory afferent nerves. Their
distribution and the immunoreactivity to various peptides
point at a role in hemodynamics and smooth muscle con-
traction. Uteri of patients with advanced endometriosis—
similar to chronic pelvic pain—show increased numbers of
nerve fibers and perivascular nerve fiber proliferation [119].
In addition, small nerve fibers were detected in the
functional layer of the eutopic endometrium in endometri-
osis patients but not in controls [120].
Compared to normal peritoneum, nerve fibers in human
peritoneal endometriotic lesions are increased [121]. In
addition, artificially induced endometriotic cysts in rats are
robustly innervated by fibers accompanying blood vessels
and extending in patterns similar to the uterus [122].
Because endometriotic tissue may be considered as a
‘vascularized autologous transplant’, its innervation has
been suggested to occur via sprouting of para- and
perivascular nerve fibers. This coordination of vasculariza-
tion and innervation has also been observed in other
transplanted organs such as the parathyroid glands [123]
and skin [124]. Immunostaining of endometriotic tissue
revealed calcitonin-gene-related peptide (CGRP)
+ and
substance P (SP)
+ sensory C and Aδ [121, 122], acetyl-
choline (Ach)
+ parasympathetic as well as tyrosine hydrox-
ylase (TH)
+ sympathetic [121] fibers (Fig. 1). CGRP
+ and
SP
+ fibers even reach the epithelium of the ectopic tissue
[122]. Endometriosis-related pain might be mediated by
these pro-inflammatory neuroactive agents. They are
increased by nerve growth factor (NGF) [125, 126], which
also sensitizes terminals of sensory nerve fibers [127].
Interestingly, intense immunoreactivity for NGF and its
receptor NGFRp75 was demonstrated near endometriotic
glands [121] (Fig. 1). Whether and how this might be
connected with immunological alterations in endometriosis
will be discussed in the course of the following section.
Stress perception, endometriosis, and sickness response
As previously outlined, cardinal symptoms of endometri-
osis are chronic pain and infertility, which may severely
interfere with the patient’s quality of life and be perceived
as a persistent stressor. To date, it is well established that
high perception of stress may trigger or aggravate the
incidence or exacerbation of diseases such as inflammatory
bowel disease [128, 129], immune dermatoses [130, 131],
or pregnancy complications such as spontaneous abortion
and pre-eclampsia [132]. Further, high levels of perceived
stress have been proposed to contribute to the progression
of endometriosis [133].
Nowadays, it is well established that high levels of
perceived stress activate the release of neurohormones such
as corticotropin-releasingh o r m o n e( C R H )a sw e l la s
adrenocorticotropic hormone (ACTH) and glucocorticoids
(GCs) largely via the hypothalamus–pituitary–adrenal
(HPA) axis [134–136]. Via these stress-related hormones,
accompanied by additional stress response mediators like
neuropeptides or neurotrophins [137, 138], immune
responses are profoundly altered [135, 136]. For example,
GCs dampen the release of IL-12, IFN-γ, and TNF-α by
antigen-presenting cells and Th1 cells, but up-regulate the
production of IL-4, IL-10, and IL-13 by Th2 cells [139,
140]. Thus, it has been proposed that the release of CRH,
ACTH, and subsequently GCs induces the selective
suppression of the Th1-mediated cellular immunity and
elicits a skew in the direction of Th2-dominated immunity.
Indeed, it has also been postulated that such Th2 shift may
actually protect the organism from systemic surpassing of
pro-inflammatory cytokines, which could have severe
tissue-injuring features [141].
However, besides such well-described immunosuppres-
sive effects of GCs, relevant examples of pro-inflammatory
actions of peripheral CRH have recently been introduced,
e.g., in the synovia of rheumatoid arthritis patients [142].
This peripheral CRH leads to proliferation of immunocytes
[143, 144] and production of IL-1, IL-2, and IL-6 [145,
146]. Moreover, CRH antagonizes some of the immuno-
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of TNF-α production [147]. Inflammation can be damp-
ened by blocking CRH at the periphery [148], as CRH
receptors occur on immune cells, e.g., on T cells, mono-
cytes [149], and mast cells [150]. Peripheral CRH may,
thus, be referred to as “immune” CRH. Immune cells such
as T cells, B cells [151], and mast cells [152] may be the
source of peripheral CRH. Besides, CRH-like immunoreac-
tivity was demonstrated in splenic nerve fibers [153], in the
dorsal horn of the spinal cord, and dorsal root ganglia as
well as sympathetic nerve fibers [154] pointing ata neuronal
source of “immune” CRH in descending nerve fibers.
Intriguingly, CRH is highly expressed in endometriotic
lesions [44] and has been proposed to stimulate mast cells
to secrete VEGF [150] (Fig. 1). This would facilitate
angiogenesis in endometriotic lesions and perpetuate the
dissemination of the disease. Thus, it may be proposed that
high levels of perceived stress promote the dissemination of
endometriosis via CRH-dependent pathways, as peripheral
CRH is found increased in response to psychological stress
[155]. It remains to be elucidated whether and how CRH
can be made attributable for the peritoneal inflammation
present in the peritoneal cavity of patients suffering from
endometriosis. In contrast to endometriotic tissue, CRH
levels in peritoneal fluid of endometriosis patients were not
different from controls; however, CRH-binding protein
(CRH-BP) is increased in advanced stages of endometri-
osis, compared to early stages or healthy controls [156],
which may be interpreted as an attempt of the body to
down-regulate high CRH levels.
Neurohormonal responses to stress also include an activa-
tion of the sympathetic nervous system with the subsequent
increase in catecholamines [137], and published evidence
strongly supports that the immune response can be regulated
via the sympathetic nervous system/catecholamines at
regional, local, and systemic levels [134]. For example,
lymphocytes express adrenergic receptors and respond to
catecholamine stimulation with the development of stress-
induced lymphocytosis, inflammation, and distinct changes
in lymphocyte trafficking, circulation, proliferation, and
cytokine production [139, 157, 158]. Because sympathetic
nerve fibers are present in endometriotic tissue, it appears
likely that—besides CRH—catecholamines contribute to the
peritoneal inflammation in endometriosis, and an increased
release of catecholamines in response to high levels of stress
could additionally perpetuate local inflammation.
Besides the classical stress-related neurohormones—the
players of the HPA axis and catecholamines—NGF and the
neuropeptide SP are now recognized as pivotal mediators of
the stress responses [131, 159–161]. SP co-functions as
neurotransmitter in the central and peripheral nervous
system in pain, anxiety, and emotional centers besides
stress [131]. Additionally, SP is a potent pro-inflammatory
mediator, as it induces the production and release of
cytokines such as IL-1, IL-6, and TNF-α and NGF [162,
163] and promotes angiogenesis during inflammation
[164]. NGF also enhances pro-inflammation and has been
proposed to increase the release of SP [161, 165, 166]. SP
and NGF derived from nerve endings induce leukocyte
recruitment and release of pro-inflammatory cytokines,
which is generally referred to as neurogenic inflammation.
Vice versa, pro-inflammatory cytokines may induce the
expression of neuropeptides such as SP and NGF and their
cognate receptors [167, 168], which might provide an
explanation for the up-regulation of NGF expression in
inflamed areas, e.g., in peritoneal endometriosis [121].
Interestingly, the activation of PAR-2 on afferent neurons,
e.g., by proteases such as mast cell tryptase, leads to
subsequent release of pro-inflammatory CGRP and SP
[169], which might provide explanation for pain during
inflammation. To date, published evidence on the expres-
sion of SP in endometriosis is very limited; some authors
report no changes of SP in endometriosis, which could be
due to the difficulties in detecting SP because it is a rather
small peptide of no more than 11 amino acids [170]. Hence,
future studies employing novel technologies such as gene
or protein arrays may allow to investigate the expression of
pain-related neurotransmitters as well as their receptors,
e.g., SP high affinity receptor neurokinin (NK)-1R [112]
on endometrial tissue. However, as outlined earlier,
Tokushige et al. [121] recently identified an increased
number of nerve fibers in peritoneal endometriotic lesions
using immunohistochemistry; in fact, these nerve fibers
were immunoreactive for SP, CGRP, Ach, NGF, and TH
(Fig. 1).
In conclusion, a hypothetical scenario on how high stress
perception might be related to endometriosis is depicted in
Fig. 3. It may be postulated, in terms of a “brain-body cross
talk”, that psychologically stressful conditions promote the
aggravation of inflammatory processes, angiogenesis, pain,
and infertility via pathways that most likely involve
catecholamines, “immune” CRH, NGF, SP, and CGRP
(Fig. 3 right), whereby the dependancy between NGF/SP
and CRH should be addressed in future experimental
settings.
Peripheral immunological events in turn signal certain
brain regions to induce the so-called sickness response
including (neuro)hormonal and behavioral changes [171].
These profound behavioral alterations are referred to as
sickness behavior, which comprises depressive-like behavior
and is characterized by reduced locomotor activity, fatigue,
hypophagia or anorexia, diminished social interactions, and
female sexual behavior [171–173]. Interestingly, such sick-
ness behavior can be experimentally provoked by peripheral
administration of IL-1 or TNF-α [172, 173]. In healthy
humans, levels of anxiety, depressed mood, and memory
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and IL-6 [174]. Brain regions identified to date comprise
structures associated with the central stress system, namely,
the hypothalamus, hippocampus, frontal/prefrontal struc-
tures, and the limbic system including the amygdala [175].
Intravenous as well as intraperitoneal applications of IL-1
result in an increased CRH production in the hypothalamus
[176, 177]. Because elevated levels of central CRH have
been associated to the abovementioned behavioral changes
during sickness [178], non-cognitive ‘inflammatory stress’
can induce behavioral and emotional alterations via increase
in central CRH. As mentioned earlier in this review, IL-1,
IL-6, and TNF-α are elevated in peritoneal fluid of
endometriosis patients. Evidently, due to the up-regulation
of pro-inflammatory cytokines not only in the peritoneal
fluid but also in the peripheral blood of patients with
endometriosis [179], this ‘inflammatory stress’ may
increase stress perception in affected patients due to the
onset of the sickness response, which includes an increase
in central CRH as well as behavioral changes and which
would aggravate the strain generated by symptoms such as
pain and infertility in terms of a ‘body–brain cross talk’
(Fig. 3,l e f t ) .
Undoubtedly, the question that arises is how peripheral
‘inflammatory stress’ can reach the central nervous system.
Here, it has been proposed that peripheral blood cytokines
bypass the blood–brain barrier (BBB) entering in the circum-
ventricular organs [180]. Secondly, these cytokines might
cross the BBB, especially when its permeability is enhanced,
e.g., in stressful conditions [181]. Thus, perceived stress
might predispose certain individuals to develop sickness
behavior during illness. Finally, vagal nervous afferents
might be involved, as suggested by experiments in rats
where behavior has been investigated before and after
vagotomy and upon intraperitoneal application of IL-1β
[182], and IL-1β-induced inhibition of social exploration
was attenuated in vagotomized rats. Because Ach
+ nerve
fibers were found in endometriotic tissue, as illustrated
above, behavioral changes mediated by vagal afferents might
play a relevant role in endometriosis (Fig. 3,l e f t ) .
In conclusion, dissemination of endometriosis may be
sustained and advanced by high levels of perceived stress
accompanying neuroendocrine-immune disequilibrium in
affected patients. This, in turn, fosters additional stressors
such as pain and infertility and induces sickness response.
As a result, stress perception is even higher, which induces
a vicious cycle of ‘brain–body–brain cross talk’ in affected
women (Fig. 3).
Animal models of endometriosis
As evident from the previous paragraphs, an in-depth
knowledge on the pathophysiology of endometriosis is
limited, mostly due to the difficulty in studying the disease
in the human [(a) need for laparoscopy, (b) painful lesions
are often very small in size and invisible from the peritoneal
cavity, and (c) high individual patient variation]. To
overcome this gap, convincing animal models are needed
in addition to clinical studies. Endometriosis is a primate-
specific disease, but primate studies can only be performed
adequately in a limited number of laboratories [183] and are
rather time-consuming. To date, the rat is one of the most
thoroughly studied laboratory animal species, and in spite
of its phylogenetic distance to the human, surgically
generated transplants of uterine fragments at different sites
of the peritoneal cavity have been shown to resemble
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Fig. 3 Hypothetical scenario for endometriosis: the ‘brain–body–brain
cross talk’. BBB blood–brain barrier, CGRP calcitonin-gene-related
peptide, CRH corticotropin-releasing hormone, NGF nerve growth
factor, SP substance P. Perceived stress aggravates peritoneal
inflammation and angiogenesis, chronic pain, and infertility in patients
with endometriosis via neuronal pathways involving catecholamines,
CRH, NGF, SP, and CGRP; this may be referred to as ‘brain–body
cross talk’ because it involves central stress response pathways.
Clearly, the aspect of infertility—a frequent clinical symptom in
patients with endometriosis—may be perceived as an additional
stressor besides stressors such as daily hassles. Peripheral ‘inflamma-
tory stress’—as described in endometriosis—and the strain of clinical
symptoms such as chronic pain may in turn induce a sickness
response, which can be entitled ‘body–brain cross talk’. Such ‘body–
brain cross talk’ may subsequently perpetuate stress perception and
trigger the release of central CRH and the onset of behavioral
alterations, i.e., sickness behavior, via elevated circulating pro-
inflammatory cytokines bypassing/crossing the BBB or via stimula-
tion of vagal afferents by peritoneal pro-inflammatory cytokines. As a
result, a vicious circle of ‘brain–body–brain cross talk’ is closed in
patients suffering from endometriosis
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Advantages and disadvantages of such rat models have
been vividly discussed, e.g., the absence of menstruation
into the peritoneal cavity in rats and consequently the lack
of retrograde menstruation as one of the key prerequisites
for the development of endometriosis. On the other hand,
rat endometrium undergoes hormone-dependent tissue
remodeling; surgically transplanted uterine tissue in the rat
mirrors human endometriotic lesions, and endometrial lesions
in rats are responsive to steroid treatment. The benefits of
using the rat model are also supported by observations that, in
rats with surgically induced endometriosis—similar to
humans—fertility and fecundity are also impaired [41, 185].
Similar to rats, mice do not menstruate and—similar to
rats—murine endometrium undergoes hormone-dependent
tissue remodeling. Further, mouse models are commonly
used in immunological research. Hence, based on the
growing evidence of a failing immune surveillance in
endometriosis, the need for a murine mouse model to study
immunological aspects of endometriosis is becoming more
and more evident. To date, a few mouse models have already
been introduced and are summarized in Table 1.I ns o m eo f
these models, human or murine endometrium is injected into
the peritoneal cavity [66, 186, 187] or fixed on the mesentery
or the peritoneum [188, 189] of either intact or ovariecto-
mized mice of different strains. In other murine models,
human endometrioma tissue was either injected subcutane-
ously in nude mice [190] or injection is performed upon
transducing whole fragments of human endometrium in vitro
by adenoviral infection with the green fluorescent protein
(GFP) cDNA before transplantation into nude mice. Implan-
tation and growth of endometriotic-like lesions could be here
non-invasively followed and repeatedly documented by in
vivo imaging [191]. Such rodent models may provide tools
fordrugtestingand/orgenetargetvalidationinendometriosis.
Clinical considerations
Current approaches to therapy for endometriosis are
surgical, directed at resecting endometriotic tissue, and
pharmacologically, aiming at inhibiting estrogenic stimula-
tion, thus reducing dissemination and disease burden.
However, despite such therapeutical approaches, endome-
triosis is still a progressive disease, and recurrences are
observed in up to 74.4% after medical treatment depending
on the stage of disease [192].
Hormonal therapeutic approaches currently used for
amelioration of endometriosis-associated pelvic pain in-
clude GnRH agonists and daily oral contraceptives used in
a cyclic or continuous regimen [118]. Because these
interventions inhibit ovulation and interfere with the cyclic
remodeling of the endometrium, the onset of pregnancy is
impossible, and one potential stressor of endometriosis, the
infertility, is not targeted. In line with such hormonal
approach in endometriosis treatment, clinical studies sug-
gest an apparent resolution of endometriosis-related symp-
toms during pregnancy, supporting the rationale of
treatments aiming at a pseudo-pregnancy regime [193]. As
mentioned earlier in this review, published evidence
suggests that progestins are effective therapies in the
treatment of pain symptoms associated with endometriosis
and ameliorate symptoms of endometriosis, as the pro-
inflammatory setting in the peritoneal cavity may be
dampened and pain receptors such as the NK1 receptor
are down-regulated [112, 194]. Clearly, the future holds
promise for highly specific therapeutic agents aiming at
targeting the pro-inflammatory setting in endometriosis.
Such approaches may include aromatase inhibitors, proges-
tins, and progesterone receptor modulators. Therapeutic
approaches aiming at diminishing inflammation also in-
clude cytokine antagonists such as the aforementioned
application of recombinant human TNF-α-binding protein-1
[65]. Further, MMP inhibitors and mast cell stabilizers such
as the flavonoid quercetin may have the potential to
ameliorate symptoms in endometriosis, as they have been
shown to inhibit the release of pro-inflammatory mediators
[195]. Interestingly, progesterone is known to suppress
MMPs and to enhance the expression of MMP inhibitors
(TIMPs) during endometrial differentiation [196]. Hence, a
combinational therapy of progestins and MMP inhibitors
may be envisioned to be highly effective in endometriosis.
Table 1 Recently published mouse models of endometriosis
Mouse strain Ovariectomy Initial tissue placement Reference #
ncr/nude (athymic) + Subcutaneous injection of human endometrioma biopsies [190]
C57BL/6 Balb/c + Intraperitoneal inoculation of murine endometrial fragments [66]
ncr/nude −/+ Intraperitoneal injection of human endometrioma biopsies [186]
Progesterone receptor −/− + Intraperitoneal fixation of murine endometrium on mesentery [188]
C57BL/6 − Intraperitoneal fixation of murine endometrial punches on peritoneum
and mesentery
[189]
C57BL/6 + Intraperitoneal injection of GFP-labeled murine endometrial fragments [187]
GFP Green fluorescent protein, PR progesterone receptor
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Profound and comprehensive insights on neuroendocrine-
immunological disequilibrium are required to fully under-
stand the pathophysiology of endometriosis and to develop
primary and secondary prevention strategies. Clearly,
multidisciplinary research activities are needed, and future
basic science and clinical trials must refrain from analyses
of single pathways, but aim at identifying currently known
key protagonists in endometriosis. In this regard, markers
and mediators introduced and summarized in the present
review may just reflect the often quoted ‘tip of the iceberg’,
but foster vivid scientific discussions and mutual research
endeavors between basic scientists and physicians aiming at
successfully targeting symptoms of this complex and
multifactorial disease that affects up to 22% of women in
their reproductive age. Obviously, the effect of psychoso-
cial counseling or psychotherapy of patients with endome-
triosis—which has noticeably been underrated in previous
studies—may be beneficial because an improved stress
management may disrupt the vicious cycle of cross talk
between peritoneal inflammation, sickness response, pain
perception, and stress.
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